Tempus AI Subsidiary Hits One Million DNA/RNA Test Milestone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Should l Buy TEM?
Source: Benzinga
- Milestone Achievement: Ambry Genetics has completed its one millionth DNA/RNA test, indicating a growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare diseases, which is expected to enhance the company's market share in precision medicine.
- Data Impact: Data from over 450,000 patients revealed that 1 in 25 positive patients would have been missed without RNA data, and the inclusion of RNA led to a 6% reduction in variants classified as uncertain, thereby improving the accuracy and clinical value of the tests.
- Market Performance: Tempus AI shares are currently priced at $58.86, trading 11.4% below the 20-day simple moving average and 23% below the 100-day simple moving average, indicating a bearish trend in the short term and reflecting market concerns about its future performance.
- Future Expectations: Analysts project a loss of 14 cents per share for 2026, with revenue estimates at $364.25 million, showing significant year-over-year growth, and despite current stock pressures, the market remains optimistic about its long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 86.00 USD with a low forecast of 76.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 52.440
Low
76.00
Averages
86.00
High
105.00
Current: 52.440
Low
76.00
Averages
86.00
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood Increases Stock Holdings Amid Market Volatility
- AMD Strong Performance: AMD's fourth-quarter revenue surged 34% year-over-year to $10.3 billion, with a 39% increase in data center revenue indicating robust market demand, despite disappointing guidance suggesting challenges ahead.
- Tesla's Transition Challenges: Tesla faces stagnant sales growth, impacted by the end of tax incentives, yet Cathie Wood's decision to increase her stake reflects confidence in the company's long-term potential amid ongoing transformation efforts.
- Tempus AI Rapid Growth: Tempus AI reported an impressive 84% revenue growth over the past nine months, establishing connections with 65% of U.S. academic medical centers and 55% of oncologists, highlighting its significant impact in the healthcare AI sector.
- Investment Opportunities Amid Market Volatility: With AMD, Tesla, and Tempus AI experiencing price corrections, Cathie Wood's active buying strategy underscores her belief in their long-term growth potential, even as market risks remain prevalent.
See More
Tempus AI Subsidiary Hits One Million DNA/RNA Test Milestone
- Milestone Achievement: Ambry Genetics has completed its one millionth DNA/RNA test, indicating a growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare diseases, which is expected to enhance the company's market share in precision medicine.
- Data Impact: Data from over 450,000 patients revealed that 1 in 25 positive patients would have been missed without RNA data, and the inclusion of RNA led to a 6% reduction in variants classified as uncertain, thereby improving the accuracy and clinical value of the tests.
- Market Performance: Tempus AI shares are currently priced at $58.86, trading 11.4% below the 20-day simple moving average and 23% below the 100-day simple moving average, indicating a bearish trend in the short term and reflecting market concerns about its future performance.
- Future Expectations: Analysts project a loss of 14 cents per share for 2026, with revenue estimates at $364.25 million, showing significant year-over-year growth, and despite current stock pressures, the market remains optimistic about its long-term growth potential.
See More
Pelosi Couple's Investment Portfolio Analysis
- Portfolio Overview: The Pelosi couple has a net worth of approximately $275 million, primarily derived from successful stock investments, particularly in large-cap tech stocks, highlighting their long-term success and influence in the investment arena.
- Transaction Details: In January 2026, the Pelosis exercised 50 call options to purchase 5,000 shares of tech giants like Alphabet, Amazon, and Nvidia, indicating their strong bullish outlook on these companies, which is expected to drive future investment returns.
- AI Investment Theme: Their investment strategy revolves around 'betting big on AI,' particularly in companies like Tempus AI and Vistra, the latter of which signed a 20-year power purchase agreement with Meta Platforms, reflecting confidence in AI growth potential.
- Investment Performance: From January 2025 to January 2026, the stocks invested by the Pelosis performed exceptionally well, with Alphabet rising 74.6% and Tempus AI soaring 121%, resulting in an overall portfolio return of approximately 41.7%, significantly outperforming the S&P 500 index's 20.3%.
See More
Analysis of Pelosi Couple's Successful Investments
- Successful Investment Case: The Pelosi couple has a net worth of approximately $275 million, largely attributed to their successful investments in large-cap tech stocks, demonstrating their long-term investment capability and market insight.
- Investment Strategy Analysis: Paul Pelosi conducts most of their investments through his San Francisco-based firm, leveraging their geographical proximity to Silicon Valley to enhance their competitive edge in tech stock investments.
- Bullish on AI Sector: The Pelosis are optimistic about three major tech stocks: Google parent Alphabet, Amazon, and Nvidia, indicating their confidence in the future growth potential of artificial intelligence and cloud computing.
- Portfolio Performance: From January 14, 2025, to January 16, 2026, the Pelosi couple's investment portfolio returned approximately 41.7%, doubling the performance of the S&P 500, showcasing the effectiveness and foresight of their investment decisions.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
See More
Cathie Wood Increases Stock Holdings Amid Market Volatility
- AMD Strong Performance: AMD's fourth-quarter revenue surged 34% year-over-year to $10.3 billion, with a 39% increase in data center revenue indicating robust market demand, despite disappointing guidance suggesting challenges ahead.
- Tesla's Transition Challenges: Tesla faces stagnant sales growth, impacted by the end of tax incentives, yet Cathie Wood's decision to increase her stake reflects confidence in the company's long-term potential amid ongoing transformation efforts.
- Tempus AI Rapid Growth: Tempus AI reported an impressive 84% revenue growth over the past nine months, establishing connections with 65% of U.S. academic medical centers and 55% of oncologists, highlighting its significant impact in the healthcare AI sector.
- Investment Opportunities Amid Market Volatility: With AMD, Tesla, and Tempus AI experiencing price corrections, Cathie Wood's active buying strategy underscores her belief in their long-term growth potential, even as market risks remain prevalent.
See More
Tempus AI Subsidiary Hits One Million DNA/RNA Test Milestone
- Milestone Achievement: Ambry Genetics has completed its one millionth DNA/RNA test, indicating a growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare diseases, which is expected to enhance the company's market share in precision medicine.
- Data Impact: Data from over 450,000 patients revealed that 1 in 25 positive patients would have been missed without RNA data, and the inclusion of RNA led to a 6% reduction in variants classified as uncertain, thereby improving the accuracy and clinical value of the tests.
- Market Performance: Tempus AI shares are currently priced at $58.86, trading 11.4% below the 20-day simple moving average and 23% below the 100-day simple moving average, indicating a bearish trend in the short term and reflecting market concerns about its future performance.
- Future Expectations: Analysts project a loss of 14 cents per share for 2026, with revenue estimates at $364.25 million, showing significant year-over-year growth, and despite current stock pressures, the market remains optimistic about its long-term growth potential.
See More
Pelosi Couple's Investment Portfolio Analysis
- Portfolio Overview: The Pelosi couple has a net worth of approximately $275 million, primarily derived from successful stock investments, particularly in large-cap tech stocks, highlighting their long-term success and influence in the investment arena.
- Transaction Details: In January 2026, the Pelosis exercised 50 call options to purchase 5,000 shares of tech giants like Alphabet, Amazon, and Nvidia, indicating their strong bullish outlook on these companies, which is expected to drive future investment returns.
- AI Investment Theme: Their investment strategy revolves around 'betting big on AI,' particularly in companies like Tempus AI and Vistra, the latter of which signed a 20-year power purchase agreement with Meta Platforms, reflecting confidence in AI growth potential.
- Investment Performance: From January 2025 to January 2026, the stocks invested by the Pelosis performed exceptionally well, with Alphabet rising 74.6% and Tempus AI soaring 121%, resulting in an overall portfolio return of approximately 41.7%, significantly outperforming the S&P 500 index's 20.3%.
See More
Analysis of Pelosi Couple's Successful Investments
- Successful Investment Case: The Pelosi couple has a net worth of approximately $275 million, largely attributed to their successful investments in large-cap tech stocks, demonstrating their long-term investment capability and market insight.
- Investment Strategy Analysis: Paul Pelosi conducts most of their investments through his San Francisco-based firm, leveraging their geographical proximity to Silicon Valley to enhance their competitive edge in tech stock investments.
- Bullish on AI Sector: The Pelosis are optimistic about three major tech stocks: Google parent Alphabet, Amazon, and Nvidia, indicating their confidence in the future growth potential of artificial intelligence and cloud computing.
- Portfolio Performance: From January 14, 2025, to January 16, 2026, the Pelosi couple's investment portfolio returned approximately 41.7%, doubling the performance of the S&P 500, showcasing the effectiveness and foresight of their investment decisions.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
See More
